Investment Opportunity in the Emerging, Innovative Technology of Cancer Detection
Armune BioScience, Inc. is a Delaware corporation with headquarters in Kalamazoo, MI. Product development and commercialization laboratories are located in Ann Arbor, MI. Basic research in support of additional product development was conducted at the University of Michigan under a Sponsored Research Agreement.
Armune is a privately held corporation and is actively seeking additional equity investments in the company to further develop and commercialize cancer-detection technology for the healthcare industry.
Armune’s intellectual property position for autoantibody technologies includes an exclusive license from the University of Michigan to US, PCT, and WO patents and patent applications. Three U.S. and two foreign patents have been issued, and there are currently four patents pending. The patents cover novel biomarkers and cancer detection technology, multiple cancers, and method of use. In addition, Armune continues to augment its IP by filing new applications based on internal discoveries.
For More Information
Contact Eli Thomssen, Chief Business Officer, at CustomerService@armune.com or call 844-4Armune (844-427-6863).